Developer says Cel-Sci's L.E.A.P.S. technology has extensive applications Print E-mail
By M.E.Garza   
Monday, 19 October 2009 03:00
While Dr. Daniel Zimmerman of Cel-Sci Corporation (AMEX:CVM) and his team have been spending a great deal of time and energy working on the company's investigational LEAPS-H1N1 treatment, this past weekend the focus shifted to another illness which causes fatigue, loss of appetite, widespread muscle aches and weakness.

New rheumatoid arthritis data presented at the American College of Rheumatology's annual meeting in Philadelphia by Dr. Zimmerman in conjunction with several collaborators from Washington Biotech, Northeastern Ohio Universities College of Medicine and BolderBiopath, indicated that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000, based upon the company's L.E.A.P.S. technology, acts to prevent or retard the permanent tissue damage caused by rheumatoid arthritis in animals.

These statistically significant results are the latest positive notch on the belt for L.E.A.P.S., but the scientific journey for technology has been a long, meticulous one.

"I've been working on this technology for over twenty years," explains Zimmerman, "We've stuck with it since 1987, firmly believing in it, being the key developer for it. Things are finally starting to take off. We're seeing now that the applications are as extensive as we thought that they would be originally in the areas of infectious diseases, autoimmune, perhaps even cancer and other types of conditions, but we've been limited in our resources so we had to concentrate on some key areas, hence the rheumatoid arthritis results."

CEL-SCI’s much discussed H1N1 treatment is based on the same treatment platform and the U.S. Food and Drug Administration (FDA) was intrigued enough by the potential of Dr. Zimmerman's work that the company was given an expedited go-ahead to proceed with its first clinical trials involving human models. The company hopes the same results which were achieved through a reduction of inflammatory response will be the same for their new H1N1 treatment for H1N1 hospitalized patients.

"Many of these patients die from the excessive inflammatory response," Geert Kersten, Chief Executive Officer of CEL-SCI said in a prepared statement. "We feel that this new data is encouraging both for this rheumatoid arthritis vaccine as well as supportive of our H1N1 treatment."

"It's really getting quite exciting," said Zimmerman. "We've done several studies and we're seeing very good therapeutic benefit of the technology as accessed by several number of criteria, it's not just one criteria."

During the presentation dealing with rheumatoid arthritis on Sunday, the researchers demonstrated the measurement of four different parameters alone for vaccine  and each of them was backed with remarkable scientific data. 

What made the medical community at the presentation take note of the CEL-2000 vaccine was it's proposed use as a treatment for the debilitating pain, stiffness and inflammation that wreaks havoc from rheumatoid arthritis.

"The therapeutic vaccination is actually a vaccine that's given after the disease symptoms have started appearing and developing, so it's not something that is given before the disease has become apparent. We're actually waiting until we see disease symptoms."

What may intrigue investors further are the technology's implications that reach beyond the H1N1 and rheumatoid arthritis spaces.

"We have some other work (in treating other diseases) which has not been presented as yet and I'm not yet at liberty to discuss that because our collaborators have not yet announced that or presented it and I don't want to preempt them on that, " explains Zimmerman. "We are looking at several different systems."


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus